Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of Namodenoson in advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis
MOH_2022-03-09_010666Phase 3Not yet recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Namodenoson with Placebo (2 arms). Planned start Mar 2022; status: not yet recruiting.
02
Drugs
namodenoson
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2022-03-09_010666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-09_010666.